Halozyme /
Elektrofi
Halozyme agrees to acquire Elektrofi in a merger
Source for the buyer and target: HALOZYME THERAPEUTICS, INC.
For the buyer and target.
“Pursuant to the Merger Agreement, Halozyme will pay (i) aggregate upfront consideration of $750 million in cash, subject to customary adjustments for Elektrofi’s debt, cash, transaction expenses and net working capital (the “ Merger Consideration ”) and (ii) up to three $50 million milestone payments contingent on three separate product regulatory approvals, in each case, in accordance with the terms and conditions set forth in the Merger Agreement.”
Published 3 Oct 2025
Open the sourceWhat happened
Halozyme Therapeutics, Inc. agreed to acquire Elektrofi, Inc. in a merger that will make Elektrofi a wholly-owned subsidiary of Halozyme. The merger agreement provides for $750 million in cash upfront, subject to customary adjustments. [01]
The agreement also provides for up to three $50 million milestone payments, contingent on three separate product regulatory approvals. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Halozyme agrees to acquire Elektrofi in a merger
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly